CVS to Pay $5M in Settlement Over Pricing Charges

Reuters

CVS Caremark Corp (NYSE:CVS) has agreed to pay $5 million to settle charges that it misrepresented the prices of some Medicare Part D drugs, the U.S. Federal Trade Commission said on Thursday.

Continue Reading Below

The $5 million will be used to reimburse seniors who paid too much, the FTC said in a statement.